山河药辅
(300452)
| 流通市值：22.64亿 | | | 总市值：28.42亿 |
| 流通股本：1.87亿 | | | 总股本：2.34亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 247,871,756.3 | 882,573,320.58 | 644,353,357.35 | 449,925,000.41 |
| 营业收入 | 247,871,756.3 | 882,573,320.58 | 644,353,357.35 | 449,925,000.41 |
| 二、营业总成本 | 200,329,332.3 | 733,237,567.43 | 526,758,558.87 | 359,882,963.63 |
| 营业成本 | 167,658,629.29 | 608,623,452.47 | 436,937,578.94 | 299,396,747.96 |
| 税金及附加 | 2,627,748.84 | 9,076,050.92 | 6,657,365.24 | 4,623,049.59 |
| 销售费用 | 7,331,103.98 | 29,409,731.88 | 22,244,761.78 | 13,914,980.78 |
| 管理费用 | 7,498,467.59 | 34,848,568.06 | 23,325,121.62 | 14,766,590.41 |
| 研发费用 | 12,333,757.33 | 40,952,648.76 | 28,749,770.86 | 21,946,221.76 |
| 财务费用 | 2,879,625.27 | 10,327,115.34 | 8,843,960.43 | 5,235,373.13 |
| 其中:利息费用 | 3,157,193.98 | 12,732,444.71 | 10,038,238.14 | 6,602,390.9 |
| 其中:利息收入 | 356,517.76 | 946,672.16 | 882,852.75 | 605,686.46 |
| 加:公允价值变动收益 | -526,013.84 | -3,134,923.69 | -6,516,151.13 | 6,292,912.56 |
| 加:投资收益 | 2,586,319.4 | 19,229,435.52 | 16,898,114.28 | 5,667,862.32 |
| 资产处置收益 | -55,806.89 | 109,338.5 | -89,632.93 | -154,096.11 |
| 资产减值损失(新) | - | -39,126,854.84 | - | - |
| 信用减值损失(新) | -12,996.67 | 2,695.63 | -59,284.68 | -59,311.99 |
| 其他收益 | 3,616,786.91 | 16,851,939.54 | 11,700,847.4 | 7,226,601.25 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 53,150,712.91 | 143,267,383.81 | 139,528,691.42 | 109,016,004.81 |
| 加:营业外收入 | 71,830.89 | 51,646.01 | 482,179.29 | 293,259.62 |
| 减:营业外支出 | 14,627.9 | 963,616.56 | 148,175.69 | 67,657.93 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 53,207,915.9 | 142,355,413.26 | 139,862,695.02 | 109,241,606.5 |
| 减:所得税费用 | 6,549,549.69 | 21,830,459.63 | 16,423,782.3 | 12,945,057.15 |
| 六、净利润 | 46,658,366.21 | 120,524,953.63 | 123,438,912.72 | 96,296,549.35 |
| 持续经营净利润 | 46,658,366.21 | 120,524,953.63 | 123,438,912.72 | 96,296,549.35 |
| 归属于母公司股东的净利润 | 47,176,895.69 | 119,424,741.26 | 122,425,859.03 | 95,533,023.67 |
| 少数股东损益 | -518,529.48 | 1,100,212.37 | 1,013,053.69 | 763,525.68 |
| (一)基本每股收益 | 0.2 | 0.51 | 0.53 | 0.41 |
| (二)稀释每股收益 | 0.19 | 0.51 | 0.52 | 0.4 |
| 九、综合收益总额 | 46,658,366.21 | 120,524,953.63 | 123,438,912.72 | 96,296,549.35 |
| 归属于母公司股东的综合收益总额 | 47,176,895.69 | 119,424,741.26 | 122,425,859.03 | 95,533,023.67 |
| 归属于少数股东的综合收益总额 | -518,529.48 | 1,100,212.37 | 1,013,053.69 | 763,525.68 |
| 公告日期 | 2025-04-23 | 2025-04-23 | 2024-10-23 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |